Comparison of Anti-IgE and Anti-IL5 Treatments on Corticosteroids Purchase for Adult Asthma, a Real-Life Insight
International Archives of Allergy and Immunology · 2025
DOI: 10.1159/000548580 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Mor Pinkas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Adelson School of Medicine, Ariel University, Ariel, Israel. Hauptthemen laut MEDLINE: Asthma, Omalizumab, Antibodies, Monoclonal, Humanized, Adrenal Cortex Hormones. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Introduction
Several biological treatments are available for patients with asthma who are not well controlled with inhaled corticosteroids (ICS) and bronchodilators. Real-life studies comparing the effectiveness of add-on biological treatments are lacking.
Methods
In this retrospective study, the population included adult patients with asthma who were treated with omalizumab and mepolizumab. The number of systemic corticosteroids (injectable and oral) and the number of ICS purchases were compared between 12 months before the first biological treatment and 12 months after.
Results
Of 173 patients, 122 were treated with omalizumab and 51 with mepolizumab. A higher proportion of females received mepolizumab than omalizumab (87% vs. 48%, respectively, p = 0.034). Omalizumab significantly reduced the number of patients who purchased corticosteroid injections from 34% to 21% (p < 0.001) but not mepolizumab. A trend toward reduction in the number of patients who purchased corticosteroid tablets was demonstrated during the year of mepolizumab treatment (from 84% to 63%, p = 0.07). For both drugs, no significant differences were found in the mean number of corticosteroid injections, tablets, and inhaler purchases between the year before and during the biological treatments.
Conclusion
Omalizumab was superior to mepolizumab in reducing the number of patients who were treated with corticosteroid injections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adelson School of Medicine, Ariel University, Ariel, Israel.
- Clinical Pharmacy Services, Department of Pharmacy, Dan-Petah-Tiqwa District, Clalit Health Services Community Division, Ramat-Gan, Israel.
- Independent Researcher, Tel-Aviv, Israel.
- Research Authority, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
- Research Unit, Dan-Petah-Tiqwa District, Clalit Health Services Community Division, Ramat-Gan, Israel.
- Managment, Dan-Petah-Tiqwa District, Clalit Health Services Community Division, Ramat-Gan, Israel.
Zitieren
APA
Pinkas, M., Cohen, J., Pinkas, N., Hazon, S., Yosef, N., Reichenberg, Y., & Shlomi, D. (2025). Comparison of Anti-IgE and Anti-IL5 Treatments on Corticosteroids Purchase for Adult Asthma, a Real-Life Insight. International Archives of Allergy and Immunology. https://doi.org/10.1159/000548580
Vancouver
Pinkas M, Cohen J, Pinkas N, Hazon S, Yosef N, Reichenberg Y, et al. Comparison of Anti-IgE and Anti-IL5 Treatments on Corticosteroids Purchase for Adult Asthma, a Real-Life Insight. International Archives of Allergy and Immunology. 2025. doi:10.1159/000548580
BibTeX
@article{Pinkas2025,
author = {Pinkas, Mor and Cohen, Jacob and Pinkas, Nadav and Hazon, Shira and Yosef, Noga and Reichenberg, Yael and Shlomi, Dekel},
title = {Comparison of Anti-IgE and Anti-IL5 Treatments on Corticosteroids Purchase for Adult Asthma, a Real-Life Insight},
journal = {International Archives of Allergy and Immunology},
year = {2025},
doi = {10.1159/000548580}
}
EUVIMED